ArticlePrzeglad gastroenterologiczny2025
Evaluation of the clinical utility of measuring serum infliximab and vedolizumab concentrations during monitoring of biologic therapy in patients with inflammatory bowel disease.
Article in Przeglad gastroenterologiczny, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Infliximab (IFX) and vedolizumab (VDZ) are monoclonal antibodies used for the treatment of inflammatory bowel diseases (IBD), such as Crohn's disease (CD) and ulcerative colitis (UC). The concentration of biologic drugs must be high enough for a therapeutic response. Aim: To evaluate the association of VDZ or IFX concentrations with the clinical condition of patients with IBD during therapy. Material and methods: We examined 82 patients with IBD treated with VDZ or IFX. Blood samples were before the administration of the drug dose. Serum drugs were determined by ELISA with RIDASCREEN kits from R-Biopharm AG. Results: The highest median serum VDZ concentrations were observed in patients with UC and endoscopic response or remission. The median serum VDZ concentration during the maintenance phase in patients with endoscopic remission remained at similar levels, while in patients without remission, a decrease was shown. Additionally, analysis of VDZ concentrations in the group of patients without endoscopic remission showed a significant decrease in drug concentration in the maintenance phase compared the induction phase ( Conclusions: The sustained serum concentrations of VDZ in patients with IBD determined in the maintenance phase confirmed a positive response to this therapy, which in practice may have significance in optimising the dosage of biological treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.